Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label crinecerfont study in adults with classic congenital adrenal hyperplasia
2025-524282-24-00Phase 3Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of crinecerfont in classic congenital adrenal hyperplasia, sponsored by Neurocrine Biosciences. Primary endpoint: Change from baseline in pre-glucocorticoid serum androstenedione at Week 24. Planned start Jul 2026; status: authorised.
02
Drugs
crinecerfont
03
Conditions
classic congenital adrenal hyperplasia
Beyond the preview
Go deeper on 2025-524282-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524282-24-00.